CD4+ guided antiretroviral treatment interruption in HIV infection: A meta-analysis

AIDS Reviews

Volumn 10, Issue 4, 2008, Pages 236-244

  Seminari, Elena ^a   De Silvestri, Annalisa ^a   Boschi, Andrea ^b   Tinelli, Carmine ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b AUSL Rimini   (Italy)

Author keywords

CD4+; HIV infection; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; QUALITY CONTROL; RETREATMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THERAPY DELAY;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 59549105717     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003; 362:22-9.
2. D'arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the Italian cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2005;38:407-16.
3. Glass T, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008;13:77-85.
4. Johnson M, Neilands T. Neuroticism, side effects, and health perceptions among HIV-infected individuals on antiretroviral medications. J Clin Psychol Med Settings. 2007;14:69-77.
5. Trotta M, Ammassari A, Murri R, et al. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS. 2008;22:291-9.
6. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the staccato randomised trial. Lancet. 2006;368:459-65.
7. Cardiello P, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis. 2005;40:594-600.
8. Giuntini R, Martinelli C, Ambu S, et al. Prolonged treatment interruption in chronic HIV infection: A new strategy? AIDS. 2005;19:209-11.
9. Krolewiecki A, Zala C, Vanzulli C, et al. Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: A randomized trial. J Acquir Immune Defic Syndr. 2006;41:425-9.
10. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS. 2004;18:439-46.
11. Mata R, Viciana P, de Alarcon A, et al. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: Clinical, virologic, and immunologic consequences. AIDS Patient Care STDS. 2005;19:550-62.
12. Mussini C, Bedini A, Borghi V, et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 × 106 cells/l. AIDS. 2005; 19:287-94.
13. Pellegrin I, Thiebaut R, Blanco P, et al. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? impact on immunovirological parameters. J Med Virol. 2005;77:164-72.
14. 3: 48-week treatment interruption in early starters Netherlands study (TRIESTAN). J Acquir Immune Defic Syndr. 2007; 44:395-400.
15. Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS. 2007;21:169-78.
16. Skiest D, Su Z, Havlir D, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS clinical trials group 5170. J Infect Dis. 2007;195:1426-36.
17. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr W, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
18. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Int J STD AIDS. 2007;18:832-4.
19. Tarwater P, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-8.
20. Thiebaut R, Pellegrin I, Chene G, et al. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 10(6) cells/l. AIDS. 2005;19:53-61.
21. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (trivacan ANRS 1269 trial): A randomised trial. Lancet. 2006;367:1981-9.
22. Altman D, Schulz K, Moher D, et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med. 2001;134:663-94.
23. Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet. 2007;370:1453-7.
24. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
26. Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-900.
27. Molina-Pinelo S, Vivancos J, De Felipe B, et al. Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption. J Acquir Immune Defic Syndr. 2006;42:203-6.
28. Fernandez Guerrero M, Rivas P, Molina M, Garcia R, De Gorgolas M. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis. 2005;41:390-4.
29. Phillips A, CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18:51-8.
30. Phillips A, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717-21.
31. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "mortalite 2000 and 2005" surveys (ANRS EN19 and mortavic). J Acquir Immune Defic Syndr 2008;48:590-8.
32. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV cohort study: Effect on mortality and treatment modification. Antivir Ther. 2007;12:1157-64.
33. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren J, Babiker A, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-55.
34. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-9.
35. Bardeguez A, Lindsey J, Shannon M, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48:408-17.
36. Kerr T, Palepu A, Barness G, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther. 2004;9:407-14.
37. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104.